Vertex Pharmaceuticals Incorporated vs Roundhill S&P 500 0DTE Covered Call Strategy ETF — how do they compare? Vertex Pharmaceuticals Incorporated trades at $478.06 (market cap $121.95B), while Roundhill S&P 500 0DTE Covered Call Strategy ETF trades at $38.7. The key difference: Vertex Pharmaceuticals Incorporated is trading nearer its 52-week high, Roundhill S&P 500 0DTE Covered Call Strategy ETF nearer its low. Which is the better fit depends on your goals.
| VRTX | XDTE | |
|---|---|---|
Market Cap | $121.95B | — |
Sector | Health | Income / Options Overlay |
52-Week High | $529.59 | $44.76 |
52-Week Low | $366.54 | $36.00 |
Enterprise Value | $116.69B | — |
Trailing returns across standard periods
Latest headlines on both assets
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio for cystic fibrosis, where Vertex therapies remain the standard of care globally. In addition to its focus on cystic fibrosis, Vertex is diversifying its pipeline through gene-editing therapies such as CTX001 for beta-thalassemia and sickle-cell disease, small-molecule inhibitors targeting acute and chronic pain using non-opioid treatments, and small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
Read more on VRTX →XDTE is an actively managed ETF that utilizes a synthetic covered call strategy on the S&P 500 Index using zero-days-to-expiration (0DTE) options. It seeks to provide high weekly income and overnight exposure to the index while mitigating some volatility through daily option premium harvesting.
Read more on XDTE →